Galactomannan detection from piperacillin-tazobactam brands available in the Brazilian market

AUTOR(ES)

Xavier, Melissa Orzechowski, Pasqualotto, Alessandro Comarú, Aquino, Valério Rodrigues, Sukiennik, Teresa Cristina Teixeira, Severo, Luiz Carlos

FONTE

Brazilian Journal of Infectious Diseases

DATA DE PUBLICAÇÃO

2009-10

RESUMO

Piperacillin-tazobactam is a broad spectrum antimicrobial agent that can cause false-positive results in the commercial Platelia Aspergillus EIA test. So far, no study has been performed in Latin America to evaluate the clinical implication of this finding. Here we studied the potential for galactomannan detection in piperacillin-tazobactam batches commercialized in the Brazilian market. Five batches from distinct laboratories were tested in duplicate in the Platelia Aspergillus EIA according to the manufacturer's instructions. Only one drug showed crossreaction at a cut-off of 0.5. Human serum was spiked with this particular drug aiming to mimic achievable piperacillin-tazobactam concentrations in the serum. Results were all negative for galactomannan detection, even at high drug concentrations. Results from this pilot study suggest that piperacillin-tazobactam might not be a clinically significant cause of false-positive results in the Platelia Aspergillus EIA test in Brazil.

Documentos Relacionados

• Assessment of biliary excretion of piperacillin-tazobactam in humans.
• Detection of Galactomannan Antigenemia in Patients Receiving Piperacillin-Tazobactam and Correlations between In Vitro, In Vivo, and Clinical Properties of the Drug-Antigen Interaction
• Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
• Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.
• Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues.